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Abstract
One of the main characteristics of the transmissible isoform of the prion protein (PrP
Sc) is its partial resistance to proteinase
K (PK) digestion. Diagnosis of prion disease typically relies upon immunodetection of PK-digested PrP
Sc following Western
blot or ELISA. More recently, researchers determined that there is a sizeable fraction of PrP
Sc that is sensitive to PK hydrolysis
(sPrP
Sc). Our group has previously reported a method to isolate this fraction by centrifugation and showed that it has
protein misfolding cyclic amplification (PMCA) converting activity. We compared the infectivity of the sPrP
Sc versus the PK-
resistant (rPrP
Sc) fractions of PrP
Sc and analyzed the biochemical characteristics of these fractions under conditions of
limited proteolysis. Our results show that sPrP
Sc and rPrP
Sc fractions have comparable degrees of infectivity and that
although they contain different sized multimers, these multimers share similar structural properties. Furthermore, the PK-
sensitive fractions of two hamster strains, 263K and Drowsy (Dy), showed strain-dependent differences in the ratios of the
sPrP
Sc to the rPrP
Sc forms of PrP
Sc. Although the sPrP
Sc and rPrP
Sc fractions have different resistance to PK-digestion, and
have previously been shown to sediment differently, and have a different distribution of multimers, they share a common
structure and phenotype.
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Introduction
The prion (PrP
Sc) is the infectious agent responsible for a suite of
different rare animal and human diseases known as transmissible
spongiform encephalopathies (TSEs) [1,2,3,4,5]. PrP
Sc is able to
convert a normal cellular prion protein (PrP
C) into PrP
Sc when
both isoforms make contact, and thereby propagate an infection.
The conversion of PrP
C into PrP
Sc involves a conformational
change of the protein in which the total amount of b-sheet
increases and that of a-helical secondary structure decreases or
perhaps disappears [6,7]. PrP
Sc is a multimer, while PrP
C is
monomeric [8,9]. These conformational differences are the only
demonstrated structural differences between PrP
Sc and PrP
C [10].
Detailed mass spectrometric analysis showed they have identical
amino acid sequences [11]. No post-translational differences have
been found between PrP
Sc and PrP
C: both share one disulfide
bond, two or less sugar antennae and a single glycophosphatidy-
linositol (GPI) anchor [12]. The composition of the sugar antennae
and the GPI anchor vary similarly in both PrP
Sc and PrP
C [13].
On the other hand, the conformational change and consequent
aggregation makes PrP
Sc insoluble in non-denaturing detergents
and partially resistant to PK digestion [1]. Thus, treatment of a
sample with 50 mg/ml of PK for 1 hour at 37uC completely
destroys PrP
C, while, typically, PrP
Sc is partially cleaved at the
amino terminal portion, leaving a PK-resistant core termed PrP
27–30.
In 1998 Safar et al. reported the existence of a subset of PrP
Sc
molecules that are completely degraded by PK, which hence were
termed, PK-sensitive PrP
Sc (sPrP
Sc) [14]. Tzaban et al. later
demonstrated for the first time that prion-infected tissues contain
sPrP
Sc molecules that form low molecular weight aggregates [15].
These authors subjected brain homogenates from scrapie-infected
animals to sucrose gradients, and found that PrP
Sc was distributed
in a continuum of aggregation sizes. The more dense fractions,
corresponding to larger multimers, were PK-resistant, whereas the
intermediate fractions, corresponding to smaller multimers, were
not. It has also been described that as much as 90% of total PrP
Sc
in the brains of individuals who had died as a consequence of
Creutzfeldt-Jakob disease (CJD) was estimated to be sPrP
Sc [16].
Different studies on other protein misfolding diseases, such as
Alzheimer’s disease, suggest that large amyloid fibrils may be a
means of protecting the host by sequestering the smaller and more
PLoS Pathogens | www.plospathogens.org 1 March 2012 | Volume 8 | Issue 3 | e1002547toxic multimers as larger less toxic fibrils [17]. In the case of prion
diseases, infectivity studies of the different sized fractions of
hamster PrP
Sc revealed a several-fold increase in infectivity for
non-fibrillar particles with masses equivalent to 14–28 PrP
molecules [18]. These PrP
Sc particle sizes correspond to the
sPrP
Sc fraction according to Tzaban and our own group’s
characterization using sucrose gradient ultracentrifugation
[15,19]. Although the definition of sPrP
Sc is operational, a
question arises: are sPrP
Sc and rPrP
Sc two populations with
different conformations or simply different sized multimers with
the same conformation?
To address this question, we investigated first the infectivity of
the sPrP
Sc vs. the PK-resistant (rPrP
Sc) fraction of hamster PrP
Sc
(263K strain). sPrP
Sc was further characterized by limited
proteolysis and mass spectrometry. Then, PrP
Sc infectivity and
strain characteristics were assessed by inoculation into Syrian
hamsters and comparison of the resulting incubation period and
lesion distribution with that obtained after inoculation with either
total PrP
Sc or the PK-resistant fraction of PrP
Sc. The obtained
results are reported here.
Results
We obtained sPrP
Sc and rPrP
Sc (263K ) fractions from our
starting total PrP
Sc by our previously described ultracentrifuga-
tion-based method [19]. When these fractions were subjected to
PK digestion for 1 h at 37uC, virtually complete degradation of
sPrP
Sc occurred after treatment with 50 mg/ml of PK whereas
partial resistance occurred with lower concentrations of the
enzyme (Figure 1). In contrast, rPrP
Sc was much more resistant
to PK under these conditions (Figure 1). These results fully agree
with our previously published work [19]. The sPrP
Sc, rPrP
Sc,
purified PrP
Sc, and the unpurified PrP
Sc material was used in our
subsequent experiments.
We performed a bioassay of normalized preparations of four
prion isolates, purified PrP
Sc, sPrP
Sc, rPrP
Sc and the unpurified
PrP
Sc-containing 0.1% brain homogenate. The amount of PrP
present in each sample was determined by a mass spectrometry-
based quantitative method [20]. The amount of residual PrP
C
present in the purified samples represents a negligible contribution
[21]. Each of the preparations was then diluted, so that each
contained approximately similar amounts of PrP. In addition,
three dilutions of each of the four normalized samples were
prepared: 1/10, 1/100, and 1/1,000 for the 0.1% brain
homogenate sample and 1/100, 1/1,000, and 1/10,000 for the
other three ones. Each of these dilution series (16 in total) was
inoculated into a set of eight Syrian hamsters (LVG) (128 total).
The dates of the appearance of clinical signs and the date of
euthanization at terminal disease were recorded [22]. These data
were plotted as a Kaplan-Meier estimate graph (Figure 2) for each
dilution of each preparation. For further clarity, they are also
presented in table form (Table S1).
Animals inoculated with the undiluted sPrP
Sc preparation got
sick sooner than those inoculated with any of the other three
undiluted preparations (P,0.01). By the 1/1000 dilution all of the
hamsters inoculated with the purified PrP
Sc (sPrP
Sc, rPrP
Sc, and
total purified PrP
Sc) had a similar incubation time, which indicates
a roughly similar infectivity. When the rPrP
Sc and purified PrP
Sc
preparations were diluted 1/10,000 all of the animals became sick.
In contrast, of the eight animals inoculated with the 1/10,000
dilution of sPrP
Sc, only seven became infected. Even after 240
days, the eighth animal showed no clinical signs and there was no
detectable PrP
Sc in its brain by mass spectrometry-based analysis
[20]. Paradoxically the sPrP
Sc shows a shorter incubation time in
the undiluted preparation (Table S2). Upon dilution of the sPrP
Sc
preparation the incubation time disproportionately increases
compared to the other purified preparations (purified PrP
Sc and
rPrP
Sc). At this point, it was not clear if these differences were due
to the possibility that our isolation procedure facilitates the
isolation of different prion strains, as has been described by Bessen
and Marsh [23], or if these differences were caused by kinetic
factors, due to the smaller size of the PrP
Sc multimers present in
the sPrP
Sc fraction [15,19].
These results show that sPrP
Sc is infectious, and that its
infectivity is comparable to that of rPrP
Sc. We wanted to see how
sPrP
Sc behaved after PK treatment. We took a sample of sPrP
Sc
and divided it into two portions. One was untreated and the other
was digested with PK (50 mg/ml of PK; 37uC; 1 h). These samples
were inoculated (ic) into two sets of six hamsters. The disease
course in both sets was observed. In the group inoculated with PK-
Figure 1. Comparison of the PK resistance of rPrP
Sc and sPrP
Sc
with varying amounts of PK. The PrP
Sc fractions, rPrP
Sc and sPrP
Sc,
were isolated (see Materials and Methods) and treated with the
indicated concentrations of PK and analyzed by WB (probed with mAb
3F4).
doi:10.1371/journal.ppat.1002547.g001
Author Summary
Prion diseases are protein misfolding disorders. Different
strains of prions are known to have variable resistance to
proteinase K (PK) digestion. Furthermore, the same strain
possesses both a PK sensitive (sPrP
Sc) and PK resistant
(rPrP
Sc) aggregate of PrP. We developed methods to
isolate the sPrP
Sc from rPrP
Sc fraction of the 263K strain of
hamster-adapted scrapie. Both fractions were infectious,
but have different physico-chemical properties. When we
analyzed the lesion targets in the brain produced by each
fraction they were essentially identical, suggesting that
they were the same strain. The biochemical differences in
the phenotypes of these two fractions are due to different
sized multimers that share common structural properties.
Furthermore, the comparison of the sensitive fractions of
two hamster strains, 263K and Drowsy (Dy), showed strain-
dependent differences in the ratios of the PK-sensitive to
the PK-resistant forms of PrP
Sc.
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Sc, animals succumbed 15 days later than in the
untreated group (Figure S1). This time interval corresponds to a
100 fold dilution of the sPrP
Sc fraction (Figure 2). Granting that
only an approximate correlation between incubation times and
titers can be surmised in our experimental conditions, given that
we did not perform a full calibration [20], this result suggests that
PK destroyed approximately 99% of the infectivity present in the
sPrP
Sc fraction. Unlike the unpurified 0.1% brain homogenate,
where the loss of infectivity upon treatment with PK is much
greater (,99%) than the loss of WB signal (,70%) [24], the loss of
signal and loss of infectivity are proportionately large (,99%) with
the sPrP
Sc fraction (Figure S1).
To assess whether sPrP
Sc is also infectious via the ip route, we
inoculated intraperitoneally two groups of animals with equal
amounts of sPrP
Sc and rPrP
Sc, respectively. Both groups
succumbed to infection, and although not statistically significant,
animals inoculated with the sPrP
Sc fraction showed an incubation
time slightly shorter (11669 dpi) than the ones inoculated with the
rPrP
Sc fraction (123614 dpi) (Figure S2). As expected, animals
inoculated ip survived longer than those inoculated ic (intracere-
bral) [25,26].
After determining that there were phenotypic differences
(incubation times) between sPrP
Sc and a complete mixture of
PrP
Sc, we explored the possibility that there were structural
differences between these two PrP
Sc fractions. We have previously
reported that, in addition to the well-known N-terminal PK
cleavage sites, around position G-90, there are other additional
cleavage sites [27]. In that study, we prepared a cleavage map for
total PrP
Sc after treatment with PK and then treatment with
NTCB. The N-terminal cleavage sites include: residues 86 (G-
86RD-178), 90 (G-90RD-178), 92 (G-92RD-178), 98 (Q-
98RD-178), and 101 (K-101RD-178). Additional cleavage sites
comprise residues 117 (A-117RD-178), 119 (G-119RD-178), 135
(S-135RD-178), 139 (M-139RD-178), 142 (G-142RD-178), and
154 (M-154RD-178) ([27] and Figure S3). We used an analogous
approach to prepare a cleavage map of sPrP
Sc. Briefly, sPrP
Sc was
digested with 1 mg/ml of PK for 30 minutes and subsequently
treated with NTCB. This reagent cyanylates free cysteines and
NaOH is subsequently used to cleave amide bonds at the N-
terminal side of the modified cysteine residues [27,28]. Given the
difficulty in identifying the GPI anchor or sugar-containing
peptides by mass spectrometry, only those free of sugar moieties
were analyzed. The NTCB reagent cleaves at the cysteine residue
at position 179, thereby separating the GPI-anchor and glycosy-
lated portion of the protein from the set of amino-terminal
truncated peptides. These peptides contain no post-translational
modifications and were analyzed by MALDI-TOF.
The MALDI-TOF analysis of the NTCB treated sPrP
Sc fraction
showed cleavage sites identical to the ones previously described for
total PrP
Sc, namely, 117, 119, 135, and 139 (Figure 3a). Curiously,
the more abundant peptides from the classic N-terminal PK-
cleavage sites (86, 90, and 92) are present in the total PrP
Sc
samples [27], but not in the sPrP
Sc fraction (Figure 3). This
suggests that the N-terminal portion of the PrP molecules present
in the sPrP
Sc fraction might be more exposed and therefore more
susceptible to PK digestion than is the N-terminal portion present
in the complete mixture of PrP
Sc. However, it should be
remembered that MALDI-TOF is not a quantitative technique
and that the signal response of larger peptides, such as (G-86RD-
178), or (G-90RD-178), is poorer than that of smaller ones.
Figure 2. Kaplan-Meier estimate graphs for dilutions of four prion preparations (263K hamster-adapted scrapie). The unpurified
PrP
Sc-containing 0.1% brain homogenate (A); the purified prions from a brain homogenate (B); the sPrP
Sc fraction (C); and the rPrP
Sc fraction (D). All
four undiluted samples contained approximately similar amounts of PrP. Only seven of the eight animals got sick after inoculation with the 10
24
dilution of sPrP
Sc fraction; the eighth remained healthy.
doi:10.1371/journal.ppat.1002547.g002
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amino-terminal sites, are prominent in sPrP
Sc as shown by WB
analysis (vide infra).
The similarity of the PK-cleavage pattern between sensitive and
total PrP
Sc is also evident when comparing the digested samples by
Western blot assay using a C-terminal antibody after PK-
treatment and deglycosylation (Figure 3b). Besides the intense
band corresponding to cleavages around position 90, 6–7
additional lower molecular weight bands are seen in both cases,
as we have previously described for total PrP
Sc [27]. Although we
do not know the identity of each band, the apparent molecular
weight of some of them could correspond with cleavages seen in
MALDI-TOF. While the relative intensities of some of the bands
vary between sPrP
Sc and total PrP
Sc, (the main band centered at
19–20 kDa smears a bit more into the 20–21 kDa region in the
sPrP
Sc sample, the ,17 kDa band is more intense in total PrP
Sc,
bands around 15, and finally, bands at ,10 and ,6 kDa are more
intense in sPrP
Sc), the overall pattern is very similar.
We wanted to ensure that in fractionating PrP
Sc, we had not
inadvertently isolated a new prion strain. We performed
comparative histopathological and immunohistochemical studies
on the left hemisphere of brains from hamsters infected with each
of the four PrP
Sc preparations. Spongiform change and PrP
deposition were detected in all cases with no detectable differences
in the PrP
Sc distribution or the morphology of the PrP
Sc
aggregates among all four groups (Figure 4). The PrP
Sc appeared
as diffuse as well as small, punctate aggregates. To assess whether
there were differences in the brain regions targeted, lesion profiles
of the hamsters inoculated with four different prion preparations
was also performed. We compared the spongiform degeneration
and PrP
Sc deposition in 6 brain regions. The results of this lesion
profile analysis suggest that the isolation procedure did not yield
different strains (Figure 5).
Western blot analysis of brain homogenates from the four
inoculated groups showed the presence of PK resistant PrP in all
groups. No differences in band patterns were detected (Figure S4).
The relative amount of sPrP
Sc in each group was assessed by
subtracting the amount PrP
Sc present in an aliquot digested with
PK from the amount of PrP
Sc present in an untreated aliquot. The
amount of PrP
Sc was determined by a previously reported mass
spectrometry-based method [20]. The proportion of sPrP
Sc
present in the brains of animals inoculated with either unpurified
brain homogenate, purified prions, rPrP
Sc or sPrP
Sc was 0.3, 0.3,
0.6 or 0.5, respectively (means of duplicate analyses). In our
previous work, we determined that sPrP
Sc accounted for between
35 and 60% of the total PrP
Sc present in the sample [19]. Thus the
relative amount of sPrP
Sc in all groups is similar to that present in
an unpurified brain homogenate.
We chose to use the drowsy (Dy) strain of hamster-adapted
prion disease in order to compare the results with those obtained
from 263K-derived prions. The phenotype of the Dy strain is very
different from that of 263K [29]. It has a much longer incubation
period and the typical symptoms are progressive lethargy and
kyphosis [23]. The Dy strain is highly susceptible to PK digestion
[30]. We wondered whether such susceptibility correlated with a
higher ratio of sensitive to resistant fraction and if this would
provide some insight into the nature of sPrP
Sc isolated from the
263K strain.
We isolated Dy sPrP
Sc using our method of isolating PK-sensitive
prions (Figure S5) [19]. The sensitive fraction of Dy was shown to
constitute approximately half of the total PrP
Sc, whereas in 263K,
the analogous PK-sensitive fraction represents a considerably lower
proportion of the total PrP
Sc (Figure S6). This could partially
explain why Dy is more PK-susceptible than 263K. These results
agree with those of Safar et al. who reported that different strains of
hamster scrapie prions contain different ratios of sensitive to
resistant PrP
Sc [14]. It should be noted that, although our PrP
Sc
purification protocol involves sonication and therefore fragmenta-
tion of large aggregates, the sonication conditions used in 263K and
Dy PrP
Sc isolation were the same.
The MALDI-TOF spectrum of the Dy sensitive fraction after
digestion with 0.1 mg/ml of PK and NTCB cleavage showed the
same internal cleavage sitesas in263K(117,119, 135,and 139) plus
others (101 (K-101RD-178) and 92 (G-92RD178)) (Figure 6) also
previously described for total PrP
Sc (Dy strain) (Figure S3 and [27]).
Discussion
Most prions have a degree of resistance to proteinase K
digestion. Digestion of prions with proteinase K yields a
Figure 3. Limited proteolysis of sPrP
Sc. a: MALDI-TOF spectrum of sPrP
Sc treated with 1 mg/ml of PK. The resulting peptides were
denatured with 6 M guanidinium chloride and cleaved with NTCB; b: Western blot analysis of total PrP
Sc (lane 1) and sPrP
Sc (lane 2) treated with 50
and 5 mg/ml of PK, respectively; C-terminal R1 antibody was used to probe the blot.
doi:10.1371/journal.ppat.1002547.g003
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infectivity that is disproportionate to the loss of protein. As
researchers examined hamster strains they realized that not all
strains of prions were equally resistant to proteinase K digestion, as
is the case with the hyper (Hy) and drowsy (Dy) strains of hamster-
adapted transmissible mink encephalopathy [23,30]. Other
researchers observed a similar phenomenon with other prions
[31,32,33,34]. Later Safar showed that PrP
Sc contained both a
proteinase K sensitive and proteinase K resistant fraction [14].
These results indicated that PrP
Sc can be both infectious and
proteinase K sensitive and that these phenotypes are a general
characteristic of prions.
Since Safar et al. reported the existence of a PK-sensitive
fraction in PrP
Sc, little has been published about its structural
Figure 4. Histopathological and immunohistochemical analyses. Sections from the brain at the level of the hippocampus of hamsters
inoculated (ic) with either the sPrP
Sc fraction (A); the rPrP
Sc fraction (B); purified prions from a brain homogenate (C); or the unpurified 10% brain
homogenate (D). Each section was stained with hematoxylin and eosin (HE) or prepared for immunohistochemical analysis using the 3F4 antibody
(PrP).
doi:10.1371/journal.ppat.1002547.g004
PK-sensitive PrP
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infectivity has been suggested [14,35], it had not been proven.
In this work we demonstrate that the sensitive fraction of PrP
Sc is
roughly as infectious as the resistant one. Highly significant is the
fact that both fractions presented similar incubation times even
when the respective inocula were diluted 1000 times. It has been
shown that when PrP
Sc was fragmented by sonication, infectious
titer was reduced because the rate of PrP
Sc clearance from the
brain increased [36]. PrP
Sc is rapidly cleared from the brain once
inoculated and the rate of clearance is influenced by the particle
size [37]. Our results indicate that both rPrP
Sc and sPrP
Sc fractions
have the same degree of infectivity indicating that the aggregation
state of PrP
Sc does not affect its infectivity. This is in contrast with
a previous report where the majority of sPrP
Sc was found to be not
infectious when measured by the scrapie cell assay [38]. Also,
Weber et al. found that extended sonication of PrP
Sc was associated
with a loss of infectivity as measured by the prolongation of the
incubation time [39]. In this case some PrP
Sc may be degraded
during sonication. In our case, total PrP
Sc is isolated first, when
Figure 5. Radar plot of the lesion profiles (scored 0–7) from six regions (1–6) of the brain from hamsters inoculated with prions.
Lesion profile scores (vide infra) reflect the spongiform degeneration and PrP
Sc deposition. Samples from the brains of two hamsters (solid grey or
black lines) inoculated with the unpurified PrP
Sc-containing 0.1% brain homogenate (A), the purified prions from a brain homogenate (B), the sPrP
Sc
fraction (C), or rPrP
Sc fraction (D). Six regions were examined: cerebellum (1), medial thalamus (2), hippocampus (3), cortex over thalamus (4), cortex-
medial (5), and cerebral peduncles (6).
doi:10.1371/journal.ppat.1002547.g005
Figure 6. Limited proteolysis of Dy sPrP
Sc. Dy sPrP
Sc was treated
with 0.1 mg/ml of PK. The resulting peptides were denatured with 6 M
guanidinium chloride and cleaved carboxy-terminally at position C179
with NTCB, and analyzed by MALDI-TOF.
doi:10.1371/journal.ppat.1002547.g006
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intermediate centrifugation speed with no further sonication. On
the other hand, hamster 263K (=Sc237) prions did not show
altered incubation times when the prion rods were fragmented by
sonication into spherical particles [40].
Several explanations may account for the similarity in infectivity
values in sPrP
Sc and rPrP
Sc. Namely, common and highly
infectious species are present in both fractions and thus are
subject to the same rate of clearance. Another possibility is the
presence of one or more cofactors that copurify with both fractions
of PrP
Sc. PrP 27–30 rods that dissociated into much smaller
detergent-lipid-protein complexes and liposomes led to a 100-fold
increase in infectivity as measured by endpoint titration [41].
Perhaps the binding of PrP
Sc to the cell membrane increases the
efficiency of disease transmission from cell to cell.
Limited proteolysis studies on the sPrP
Sc fraction of 263K and Dy
indicate that, as in total PrP
Sc, the sensitive fraction is also composed
ofalternatingPK-resistant stretchesinterspersed withPK-susceptible
stretches. The relatively small variations in intensity of some of the
PK-resistant bands detected by SDS-PAGE (Fig. 3b), could be
interpreted as corresponding to differences in accessibility of the PK-
resistant stretches involved, but the global emerging picture is one of
a shared basic structural organization.
This result emphasizes the fact that the difference between
sensitive and resistant PrP
Sc seems to be the previously described
different size of the aggregates and not the conformation of their
respective aggregates [15,19]. Our data provide information on
the N-terminal half of the protein only, therefore we cannot rule
out differences in the C-terminal portion.
As we mentioned in the introduction, the sensitive fraction of
263K varies between 20–40% of the total PrP
Sc. Despite this
variability, the amount of sensitive PrP
Sc obtained for 263K was
always less than that for Dy. This result, previously reported by
Safar et al. [14], would indicate that a specific ratio of sensitive to
resistant exists for each strain. This author also reported that the
incubation time of a given prion strain is directly proportional to
the level of protease-sensitive PrP
Sc [14]. According to Deleault et
al., variations in the sPrP
Sc:rPrP
Sc ratio between different prion
strains appear to be an incidental product rather than a strain
property [42]. Nevertheless, we want to point out that for hamster-
adapted prion diseases the PK-susceptibility seems to directly
correlate with the proportion of sPrP
Sc present in the strain.
In summary, we have shown that sPrP
Sc is fully infectious, and
that its infectivity can be reduced by approximately 99% by
treatment with PK (50 mg/mL; 1 hr). sPrP
Sc appears to share the
same basic architecture with rPrP
Sc, as judged by the generation of
similar fragmentation patterns by limited proteolysis with PK as
seen in the WB and MALDI analysis. This, together with the fact
that sPrP
Sc induces a disease with signs and histopathological and
lesion profiles that are essentially identical to those induced by
total or rPrP
Sc, strongly suggests that sPrP
Sc differs from rPrP
Sc,a s
previously shown, just in its smaller size, i.e., being made up of
fewer PrP units [15,19]. On the other hand, the fact that different
prion strains are characterized by different relative ratios of
sPrP
Sc:rPrP
Sc suggests that sPrP
Sc might play an important role in
key properties of strains. Finally, sPrP
Sc, which is soluble in
detergent-containing solutions, might prove to be useful in studies
aimed at elucidating the structure of PrP
Sc.
Materials and Methods
Ethics statement
Animal experiments were carried out in accordance with the
recommendations contained in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. The
procedures were governed by a protocol that was approved by the
Institutional Animal Care and Use Committee of the United
States Department of Agriculture, Agricultural Research Service,
Albany, CA (Protocol Number: P-10-3). All surgery was performed
under isoflurane anaesthesia, and all efforts were made to
minimize the suffering of the animals. The small numbers of
experiments carried out at the University of Santiago de
Compostela were approved by the University Ethics Committee,
in accordance with the European Union Council Directive 86/
609/EEC.
Isolation of total PrP
Sc and sPrP
Sc
PrP
Sc was isolated from brains of terminally ill Syrian hamsters
infected intracranially (ic) with the 263K strain of scrapie using a
slightly modified version of the procedure of Diringer et al. [43]. A
cocktail of protease inhibitors (Complete, Roche Diagnostics,
Penzberg, Germany) at a final concentration of 16was used in all
buffers throughout the procedure up to the penultimate pellet, as
defined in the mentioned study [43]. The final pellet was
resuspended in 20 mM Tris (pH 8.5) containing 1% sarkosyl
and no protease inhibitors, at concentrations between 1–2 mg/ml.
The stock suspension thus prepared was aliquoted and frozen until
further use; its purity was assessed by SDS-PAGE with Coomassie
blue staining, and estimated to be approximately 80%. sPrP
Sc was
isolated from total PrP
Sc by ultracentrifugation at an intermediate
speed [19]. A 50–150 ml portion of the PrP
Sc stock was
homogenized by application of 3 sonication pulses of 1 s each,
and spun in a Beckman TLX ultracentrifuge (Beckman, Fullerton,
CA) using a TLA-120-1 rotor at 40,000 rpm (56,806 g) for
2 hours at 20uC. The supernatant was collected and the pellet was
resuspended by sonication in a volume of 20 mM Tris (pH 8.5)
containing 1% sarkosyl equivalent to that of the supernatant.
Fractions of supernatant and pellet were treated with 50 mg/ml of
PK at 37uC during 1 hour; the reaction was terminated with
2 mM Pefabloc (Fluka, St. Louis, MO), and a fraction subjected to
SDS-PAGE and either stained with Coomassie brilliant blue or
transferred to a PVDF membrane (Immobilon-P, Millipore,
Billerica, MA, USA) and analyzed by Western blotting using
mAb 3F4 (Dako, Glostrup, Denmark). The supernatant fraction is
sPrP
Sc, and the pellet fraction, PK-resistant PrP
Sc (rPrP
Sc). The
concentration of PrP
Sc was estimated in each of these samples and
in brain homogenates. PrP
Sc was isolated by ultracentrifugation
using the method of Bolton et al. [44], with slight modifications
[20]. The resulting pellets were dissolved in 200 mLo f6 M
guanidinium chloride and allowed to stand at RT for 24 hours to
inactivate the PrP
Sc [45]. The inactivated prion solutions were
precipitated with methanol and subjected to analysis by mass
spectrometry using previously described methods [20,21]. Briefly,
pellets were dissolved in 0.01% aqueous beta-octylglucopyranoside
(BOG) and [
13C5,
15N]-VVEQMCTTQYQK added as internal
standard. The samples were then sequentially reduced, alkylated
and digested with trypsin. NanoLC/MS/MS was carried out with
an Applied Biosystems (ABI/MDS Sciex, Toronto, Canada)
model 4000 Q-Trap instrument equipped with a nano-electro-
spray ionization source. The mass spectrometer was operated in
multiple reaction monitoring (MRM) mode, alternating between
detection of VVEQMCTTQYQK (precursor ion m/z of 757.8,
product ion of m/z 171.1) and [
13C5,
15N]-VVEQMCTTQYQK
(precursor ion m/z of 760.8, product ion of m/z 177.1).
Quantitation was done with the Intelliquan quantitation algorithm
of Analyst 1.4.1 software (Applied Biosystems) using default
parameters [20,21].
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Four prion isolates, 0.1% brain homogenate, purified PrP
Sc,
sPrP
Sc, and rPrP
Sc, were diluted to yield four corresponding
solutions containing 1.560.4 ng of PrP per 50 mL of sample,
except in the case of the 0.1% brain homogenate, which contained
0.7 ng of PrP per 50 mL of sample (vide supra). A portion of each
of these normalized solutions was diluted 100-fold, 1,000-fold and
10,000-fold into sterile phosphate buffered saline (PBS) to yield a
set of four dilutions (including the undiluted material) for each of
the prion isolates; in the case of the 0.1% brain homogenate
sample, dilutions were 10-fold, 100-fold, and 1,000-fold. Fifty
microliters of each dilution were ic inoculated into the right
cerebral hemisphere of a four week old anesthetized female
hamster. Eight animals were used per isolate/dilution.
The 128 animals were placed in cages (2 per cage) and observed
for clinical signs. The first clinical sign to be observed and its date
of occurrence recorded was an exaggerated startle response. A
progression of clinical signs followed, including an exaggerated
startle response that became more pronounced over time, ataxic
gait whose severity increased with time, limb rigidity, characteristic
head bobbing, and progressive lethargy. When the animals could
no longer be roused from their recumbency to feed and drink
water, they were humanely euthanized. The incubation time was
measured (in days) as the time between inoculation and
euthanization.
After 240 days one of the inoculated animals (sPrP
Sc; 10,000-
fold dilution) animals remained healthy. The animal was
euthanized and its brain removed. The brain was analyzed for
the presence of PrP 27–30 by mass spectrometry [20]. There was
no evidence of PrP 27–30 present in the brain.
In a separate experiment, two groups of 6 animals were
inoculated ic with either 50 ml of a sample containing ,40 ng of
sPrP
Sc or the same volume of sPrP
Sc treated with 50 mg/ml of PK
for 1 h at 37uC, followed by quenching of PK with 2 mM
Pefabloc. Infection progression was monitored as described above,
and approximate infectivity titers of the PK-treated and untreated
sPrP
Sc samples were estimated by incubation period assay
according to the procedure of Prusiner et al. [22].
Finally, two groups of 6 animals were intraperitoneally (ip)
inoculated with 150 ml volumes of sPrP
Sc and rPrP
Sc prion isolates
containing ,125 ng of PrP each, and the course of infection
observed as described above. The amount of PrP
Sc in these two
samples was calculated approximately by comparison with a
recombinant Syrian hamster (rSha) PrP (90–231) standard (a
generous gift of Giuseppe Legname) after deglycosylation with
PNGase F (New England Biolabs, Ipswich, MA, USA) and
Western blotting with mAb 3F4.
Histopathology and immunohistochemical stains
Four mm thick sections were cut onto positively charged
silanized glass slides and stained with hematoxylin and eosin, or
immunostained using an antibody for PrP (3F4). Immunohisto-
chemical stains for PrP were performed entirely on an automated
Discovery XT staining apparatus (Ventana Medical Systems, Oro
Valley, AZ) using a DAB Map XT Detection Kit (Ventana
Medical Systems). Sections were deparaffinised and then washed
in distilled water for 5 min. Epitope exposure was performed by
heating sections to 100uC in a citrate buffer for 12 minutes. After
treatment with protease 2 (Ventana Medical Systems) for
24 minutes, sections were incubated with anti-PrP 3F4 for
60 min and PrP was detected using HRP-conjugated antibodies
and a DAB substrate.
Lesion profiling
We selected 6 anatomic brain regions in accordance with
previous strain typing protocols [46,47] from 2 hamsters per
group. We scored spongiosis on a scale of 0–4 (not detectable,
mild, moderate, severe and status spongiosus) and PrP immunolog-
ical reactivity on a 0–3 scale (not detectable, mild, moderate,
severe). A sum of the two scores resulted in the value obtained for
the lesion profile for the individual animal. The ‘radar plots’ depict
the scores for spongiform changes and PrP deposition. Numbers
correspond to the following brain regions: (1) cerebellum, (2)
medial thalamus, (3) hippocampus, (4) medial cerebral cortex
dorsal to hippocampus, (5) medial cerebral cortex dorsal to
septum, (6) white matter at cerebellar peduncles. Investigators
blinded to animal identification performed histological analyses.
Biochemical characterization and quantitation of PrP
Sc in
brains of inoculated animals
PrP
Sc was detected in brain homogenates of inoculated animals
by Western blot using mAb 3F4 (primary antibody) and goat anti-
mouse Fc (secondary antibody) (Sigma-Aldrich, St. Louis, MO).
To assess the relative amount of sPrP
Sc and rPrP
Sc in animals
inoculated with the four different inocula described, duplicate
PrP
Sc samples were isolated from the brains of inoculated hamsters
using the method of Bolton et al. [44] with slight modifications
[20]. The resulting pellets were either dissolved in 200 mLo f6M
guanidinium chloride (Sigma-Aldrich, St. Louis, MO) or resus-
pended in 0.1% Z 3,14-T-8.5 (0.1% 3-(N,N-dimethylmyristyl-
ammonium)propane sulfonate; 20 mM Tris pH 8.5). The 6 M
guanidinium chloride solutions were allowed to stand for 24 hours
at RT to inactivate the PrP
Sc [45]. The samples suspended in
0.1% Z 3,14-T-8.5 were sonicated. After sonication, PK was
added to make a final concentration of 5 mg/mL. The PK was
permitted to react for 1 hour at 37uC. The reaction was quenched
by addition of a sufficient amount of phenylmethylsulfonyl fluoride
(PMSF) (Sigma-Aldrich, St. Louis, MO) to achieve a final
concentration of 1 mM. Enough solid guanidinium chloride was
then added to make a 6 M solution, which was left to stand for
24 hours at RT to inactivate the prions. The inactivated prion
solutions were precipitated with methanol and the amount of PrP
present in the sample was determined by mass spectrometry (vide
supra) [20,21].
NTCB cleavage reaction of PrP
Sc samples
All buffers and reagents were prepared fresh for the 2-nitro-5-
thiocyanatobenzoic acid (NTCB) reactions. Between 15–20 mgo f
purified PrP
Sc was reduced in 2 mM DTT for 1 h at 37uC under
denaturing conditions (6 M guanidinium chloride and 100 mM
Tris buffer pH 8). In the same buffer, samples were cyanylated in
10 mM 2-nitro-5-(thiocyanato)-benzoate (NTCB) for 30 minutes
at RT. After methanol precipitation, samples were redissolved in
6 M guanidinium chloride, 100 mM Tris buffer pH 8. PrP
Sc,
specifically cyanylated at the reactive thiols, was cleaved by
alkaline hydrolysis with 150 mM NaOH for 15 minutes at 37uC.
The NTCB reaction was terminated by addition of trifluoroacetic
acid (TFA) to a final pH of 2–3. PrP
Sc peptides were isolated from
the reaction mixture using C-18 ZipTips (Millipore) according to
the manufacturer’s instructions. Peptides were eluted from the tips
in 10 ml of 50% acetonitrile, 0.1% TFA and used directly for
MALDI analysis.
MALDI mass spectrometry
A2mL portion of the PrP
Sc peptide sample was mixed with an
equal volume of a saturated solution of sinapinic acid in
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mixture was spotted onto a Bruker sample plate, allowed to air-
dry, and analyzed using a Bruker Autoflex MALDI instrument in
linear mode. The laser frequency was 25 Hz; pulsed ion extraction
was set at a value of 140–150 ns. Repeated laser shots, typically
25–30, were averaged.
Analysis of PK-resistant fragments of sPrP
Sc and total
PrP
Sc by Western blot
PK-treated samples were deglycosylated with PNGase F (New
England Biolabs, Ipswich, MA, USA) at 37uC for 48 h, according
to the manufacturer’s instructions, followed by precipitation with
ice-cold 85% MetOH. Pellets were boiled in 10 ml of reducing
tricine sample buffer (BioRad, Hercules, CA, USA). Tricine SDS-
PAGE [48] was carried out using 10–20% Tris-Tricine/Peptide
Precast gels (BioRad), in a Criterion electrophoresis system
(BioRad). The cathode buffer was Tris-Tricine-SDS buffer
(Sigma-Aldrich) and the anode buffer, 100 mM Tris-HCl,
pH 8.9. Electrophoresis was performed at a constant voltage of
125 volts for 200 minutes, on ice. After electroblotting on PVDF
membranes, these were probed with antibody R1 (a generous gift
from Hanna Serban, UCSF), which recognizes residues 226–231.
Peroxidase-labeled anti-human antibody was used as the second-
ary antibody.
Supporting Information
Figure S1 Loss of infectivity of sPrP
Sc upon treatment with
50 mg/ml of PK.
(TIF)
Figure S2 Incubation time of sPrP
Sc and rPrP
Sc inoculated by
the intraperitoneal route.
(TIF)
Figure S3 MALDI-TOF spectrum of PrP
Sc treated with 1 mg/
ml of PK, showing the presence of cleavage sites. Adapted from
Sajnani et al. (2008) J Mol Biol 382: 88–98, with permission from
Elsevier Ltd. The Boulevard, Langford Lane, Kidlington, Oxford
OX5 1GB UK.
(TIF)
Figure S4 Western blots of PrP
Sc isolated from the brains of
hamsters inoculated with unpurified brain homogenate, purified
prions from a brain homogenate, purified rPrP
Sc, or purified
sPrP
Sc. Lanes 1, 2, and 9, 10: duplicate animals inoculated with
unpurified brain homogenate. Lanes 3, 4, and 11, 12: duplicate
animals inoculated with purified PrP
Sc from a brain homogenate.
Lanes 5, 6, and 13, 14: duplicate animals inoculated with rPrP
Sc.
Lanes 7, 8, and 15, 16: duplicate animals inoculated with sPrP
Sc.
The equivalent of 5 mg of brain tissue was loaded in each lane.
Blots were probed with mAb 3F4 (primary antibody) and goat
anti-mouse Fc (secondary antibody).
(TIF)
Figure S5 Comparison of the PK resistance of Dy rPrP
Sc and
sPrP
Sc. Dy PrP
Sc fractions, rPrP
Sc (r) and sPrP
Sc (s), were isolated
(see Materials and Methods) and treated with the indicated
concentrations of PK and analyzed by WB (probed with mAb
3F4).
(TIF)
Figure S6 Relative amounts of sPrP
Sc in 263K and Dy PrP
Sc.
Samples were probed with mAb 3F4.
(TIF)
Table S1 Table of Kaplan-Meier endpoint data. Tabular
summary of the Kaplan-Meier estimate graphs for dilutions of
four prion preparations (263K hamster-adapted scrapie). The
unpurified PrP
Sc-containing 0.1% brain homogenate (Unpurified
brain homogenate); the purified prions from a brain homogenate
(purified prions); the PK sensitive prion fraction (sPrP
Sc); and the
PK resistant prion fraction (rPrP
Sc). The data represents the time
from inoculation to euthanization 6 SD, as measured in days.
Eight animals were used per dilution. Some dilutions were not
done (n.d.). Only seven of the eight animals got sick after
inoculation with the 10
24 dilution of sPrP
Sc fraction; the eighth
remained healthy.
(DOC)
Table S2 Table of P-values for t-tests. The t-test was used to
compare the Kaplan-Meier estimate data for the unpurified prions
(0.1% BH), purified prions, PK resistant prions (rPrP
Sc), and the
PK-sensitive prions (sPrP
Sc). The listed p-value is the result of a
comparison of the Kaplan-Meier data for a row with that of a
column. Each of the four dilutions (10
20,1 0
22,1 0
23, and 10
24)i s
in a separate table. A statistically significant difference (Sig) means
that the P-value (in parentheses) is greater than or equal to 0.99. A
statistically insignificant difference (NSig) means the P-value that is
less than 0.99.
(TIF)
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